Andrew Tepperman

Vice President
Andrew Tepperman | Life Sciences Litigation | Charles River Associates

Dr. Andrew Tepperman is a vice president in CRA’s Life Sciences Practice.  Dr. Tepperman has over two decades of experience assisting clients with high-stakes economic and damages issues in intellectual property, antitrust, and government litigation, and international arbitration.

In intellectual property disputes, Dr. Tepperman advises clients on damages in patent and trade secret matters and assesses commercial success and irreparable harm.  Across a range of antitrust assignments, he has regularly evaluated market power and competitive effects associated with various types of conduct, including patent settlement agreements, vertical restraints, price-fixing, and claims based on the use of intellectual property rights.  His government engagements have addressed economic and industry issues in fraud, nuisance, and regulatory lawsuits, along with tax and transfer pricing disputes.  In breach of contract matters, he has analyzed business and economic considerations relevant to contract performance as well as damages.

Dr. Tepperman’s practice has an emphasis on clients in the life sciences sector, including pharmaceutical, biologic, device, and diagnostic companies. He also has extensive experience addressing damages and further economic issues for clients in the technology sector and other industries. Dr. Tepperman has served as a testifying expert in matters before Canadian, US, and UK courts, and has testified at trial on multiple occasions.  He has advised clients on matters before regulatory agencies, including the Canadian Competition Bureau.

Dr. Tepperman joined CRA in 2001, upon completing his PhD in economics from the University of Toronto.  His doctoral dissertation focused on the strategic use by companies of intellectual property rights and economic implications of that use.

Selected Engagements

  • 01
    High-profile US patent litigation regarding HIV medications
    CRA was retained by plaintiffs ViiV Healthcare and other companies in their high-profile US patent litigation against Gilead Sciences, Inc., regarding HIV...
    View engagement
  • 02
    CRA addressed a claim that a company had improperly failed to pay required development milestones upon termination of a drug development program
    In litigation before the Delaware Court of Chancery, a CRA expert was asked to address the basis for a company’s decision to terminate the development of a...
    View engagement
  • 03
    ANDA challenge - Shire, Sanofi-Aventis, and Firazyr
    Shire, Sanofi-Aventis and Firazyr CRA consultants advised counsel to Shire Orphan Therapies, LLC (Shire) and Sanofi-Aventis Deutschland GMBH (Sanofi-Aventis)...
    View engagement